Saudi Venture Capital Company (SVC)

Saudi Venture Capital Company (SVC) is a Riyadh-based, government-backed fund of funds that anchors Saudi Arabia’s venture capital and venture debt ecosystem. The firm is not a direct investor in startups in the conventional VC sense; instead, it deploys capital into other VC and debt funds, catalyzing the broader private capital spectrum across strategic sectors including digital health and health IT. Founders should approach SVC indirectly: by raising from the GP funds that SVC backs, you are de facto raising from SVC.

The healthcare AI thesis is read through the LP lens. SVC’s strategic mandate is to deepen the Saudi venture ecosystem in line with Vision 2030 priorities, which include digital health, AI, and other technology-enabled health and life sciences segments. For founders, the practical implication is that SVC-backed GP funds operating in MENA are likely to have additional ammunition, longer time horizons, and clearer mandates to back Saudi-relevant healthcare technology. The right founders to engage with SVC-affiliated GP networks are those building products with credible Saudi or pan-GCC commercial relevance.

Geographically, SVC’s leverage is the Saudi market itself, which is large, well-funded, and structurally underserved by venture-grade healthcare technology. Founders willing to establish a Saudi presence (regional office, regulatory registration, partnership with a Saudi health system or operator) gain meaningful preferential access to capital from SVC-backed GPs. For founders without Saudi or GCC ambitions, the strategic logic of going through SVC is thin.

The right entry path is not direct contact with SVC; it is via the firm’s roster of backed GP funds, which is published on the SVC website. Identify two or three SVC-backed funds whose stage, sector, and check size match your raise, then route warm intros through their portfolio founders or affiliated angels. The pitch into a GP should still be tailored to that fund’s thesis; SVC’s role is upstream.

Caveats. Government-backed capital introduces regulatory and reporting expectations that downstream founders may inherit through GP commitments. Saudi market dynamics evolve quickly with Vision 2030 sector priorities; what is favored today may shift. Founders with international cap tables should plan for the political and regulatory considerations that come with Saudi-affiliated capital, particularly for cross-border M&A and listing scenarios. Treat SVC as an ecosystem-level signal that capital and policy support are aligned in Saudi healthcare technology, and route your raise through the appropriate downstream GPs accordingly.